Navigation Links
A Combined Heart Pill-developed by Dr. Reddy’

Dr. Reddy’s, the Indian pharma giant has decided to join hands with the University of Auckland, //New Zealand to begin Global trials of a new fixed dose combination or “polypills” to prevent strokes and heart attacks.

The polypill will combine four drugs- aspirin, statin(to reduce cholesterol) and two drugs to prevent hypertension. The trial will check the reliability of the pill when it comes to safety and its effectiveness when consumed as one pill.

Investments of Dr. Reddy’s in the trial would come up to $7.5 million, and The Health Research Council, New Zealand has invested U.S. $241,055.

Dr. Reddy’s has initiated the trial six months ago, Satish Reddy, COO and managing director of Dr. Reddy’s said, “Since all medicines in the polypill are already prescribed to heart attack patients, we don’t anticipate any problem with polypill trial.”

Anyway, the plan of having a global trial will assess the success of using the polypill in different populations. The trial will begin by the second quarter of 2007, and would involve 600 people from five continents.

Apart from people from India and New Zealand, the other countries involved in the global trial would be South Africa, China, Australia, Brazil, the United Kingdom and the United States.

It took three years for the drug company to formulate this pill. Mr.Reddy’s claims this pill to be “single most important initiative of the decade” by his firm. He also said, “We should be able to introduce the drug for secondary indication [prescriptions to stroke/heart attack patients] by mid-2007.”

Affordability of the polypill

The cost of this pill is taken to prime importance since it is to be used in developing countries. Dr.Reddy’s assured, “Our intention is to see that one month’s medication costs less than Rs. 100 [U.S. $2.20]. The combination is not going to bring us big money, but it will help the patients as they get all four pills co mbined.”

Trials at Global Level

Professor Anthony Rodgers working at the University of Auckland’s, belonging to the clinical trials research unit is going to lead the trial. He has been an advisory to WHO and is also a world-renowned clinical trial expert.

Prof. Rodgers claims that this combined pill will prove to be more effective than four medicines. He said, “Research shows that people with chronic diseases, like heart disease, take only half their medications, they forget, or they feel well, so think they don’t need to take their pills. However, that creates a gap in their treatment, which can have serious consequences for some patients.”

Thus he believes that this oil is a more practical and easy solution to cardiac ailments.

Prof. Rodgers said that the first trial would involve 5000 people moderately prone to cardiac ailments. He said, “The first trial will confirm whether the polypill lowers blood pressure and cholesterol, if it goes ahead, this second trial would confirm the pill’s ability to prevent heart attacks and strokes.”
Source-Medindia
KOM
'"/>




Related medicine news :

1. Combined scan gives exact cancer diagnosis
2. A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss
3. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
4. Vision Loss in Elderly Caused By Combined Effect of Genes and Bacterium
5. Exercise Combined with Dialysis Yields Better Results
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. A Combined Research for Producing Chlamydia Vaccine Begins
8. Combined Ingredients may Cut Cholesterol Levels
9. Combined Imaging Approach may Provide Better Identification of Difficult-to-diagnose Brain Clots
10. Combined Imaging Approach may Be Effective in Diagnosing Some Brain Clots
11. One in Three Heart Attack Patients Have No Chest Pains
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care ... a top priority because it’s not if you will be attacked, but when.” However, ... it comes to digital health care. , Improvements in auditing and monitoring have taken ...
(Date:2/24/2017)... ... ... With ProGlass Prism users now have the ability to simulate prism distortions ... rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor point, ... users are given the tools and effects to generate a fractal prismatic displacement ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Club in Miami Beach to host its Swirl: Miami Wine Tasting Event on ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price ... in the global Autism Spectrum Disorder market. The research answers ... key drugs marketed for Autism Spectrum Disorder and their clinical attributes? ...
Breaking Medicine Technology: